Literature DB >> 30449731

Evaluation of intranasal delivery route of drug administration for brain targeting.

Franciska Erdő1, Luca Anna Bors2, Dániel Farkas2, Ágnes Bajza2, Sveinbjörn Gizurarson3.   

Abstract

The acute or chronic drug treatments for different neurodegenerative and psychiatric disorders are challenging from several aspects. The low bioavailability and limited brain exposure of oral drugs, the rapid metabolism, elimination, the unwanted side effects and also the high dose to be added mean both inconvenience for the patients and high costs for the patients, their family and the society. The reason of low brain penetration of the compounds is that they have to overcome the blood-brain barrier which protects the brain against xenobiotics. Intranasal drug administration is one of the promising options to bypass blood-brain barrier, to reduce the systemic adverse effects of the drugs and to lower the doses to be administered. Furthermore, the drugs administered using nasal route have usually higher bioavailability, less side effects and result in higher brain exposure at similar dosage than the oral drugs. In this review the focus is on giving an overview on the anatomical and cellular structure of nasal cavity and absorption surface. It presents some possibilities to enhance the drug penetration through the nasal barrier and summarizes some in vitro, ex vivo and in vivo technologies to test the drug delivery across the nasal epithelium into the brain. Finally, the authors give a critical evaluation of the nasal route of administration showing its main advantages and limitations of this delivery route for CNS drug targeting.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CNS indication; Delivery enhancer techniques; Drug delivery; Intranasal administration; Transporter interactions

Mesh:

Year:  2018        PMID: 30449731     DOI: 10.1016/j.brainresbull.2018.10.009

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  114 in total

1.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

Review 2.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

3.  Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats.

Authors:  Noha Nafee; Abd El Rahman Ameen; Osama Y Abdallah
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

4.  Development of MicroRNA-Based Therapeutics for Vascular Disease.

Authors:  Kia J Jones; Charles D Searles
Journal:  Circ Res       Date:  2020-10-08       Impact factor: 17.367

Review 5.  Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.

Authors:  Madhur Kulkarni; Niserga Sawant; Anjali Kolapkar; Aishwarya Huprikar; Namita Desai
Journal:  AAPS PharmSciTech       Date:  2021-04-28       Impact factor: 3.246

6.  Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.

Authors:  Smrithi Padmakumar; Gregory Jones; Grishma Pawar; Olga Khorkova; Jane Hsiao; Jonghan Kim; Mansoor M Amiji; Benjamin S Bleier
Journal:  J Control Release       Date:  2021-01-21       Impact factor: 9.776

7.  Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions.

Authors:  Neeraj Prabhakar; Joni Merisaari; Vadim Le Joncour; Markus Peurla; Didem Şen Karaman; Eudald Casals; Pirjo Laakkonen; Jukka Westermarck; Jessica M Rosenholm
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 8.  Macrophage reprogramming for therapy.

Authors:  Valentina M T Bart; Robert J Pickering; Philip R Taylor; Natacha Ipseiz
Journal:  Immunology       Date:  2021-01-25       Impact factor: 7.215

9.  Crocetin as New Cross-Linker for Bioactive Sericin Nanoparticles.

Authors:  Sara Perteghella; Giovanna Rassu; Elisabetta Gavini; Antonella Obinu; Elia Bari; Delia Mandracchia; Maria Cristina Bonferoni; Paolo Giunchedi; Maria Luisa Torre
Journal:  Pharmaceutics       Date:  2021-05-09       Impact factor: 6.321

10.  Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury.

Authors:  Haihong Zhou; Furong Sun; Mingqian Ou; Yu Zhang; Meijun Lin; Liqin Song; Yangsheng Yu; Haojie Liao; Weihao Fan; Huaijie Xing; Minhua Li; Kui Zhao; Xiaolian Wu; Yuanhong Sun; Chunmei Liang; Yujie Cai; Lili Cui
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.